85,818 Shares in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Purchased by Boothbay Fund Management LLC

Boothbay Fund Management LLC bought a new stake in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 85,818 shares of the company's stock, valued at approximately $716,000. Boothbay Fund Management LLC owned 0.16% of Zevra Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. bought a new position in Zevra Therapeutics in the fourth quarter valued at about $94,000. Virtu Financial LLC bought a new stake in Zevra Therapeutics during the third quarter valued at about $127,000. Invesco Ltd. increased its position in Zevra Therapeutics by 19.6% in the fourth quarter. Invesco Ltd. now owns 18,384 shares of the company's stock worth $153,000 after buying an additional 3,007 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Zevra Therapeutics by 51.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 20,565 shares of the company's stock worth $172,000 after buying an additional 6,966 shares during the period. Finally, SG Americas Securities LLC lifted its position in shares of Zevra Therapeutics by 54.6% during the 4th quarter. SG Americas Securities LLC now owns 23,500 shares of the company's stock valued at $196,000 after buying an additional 8,302 shares in the last quarter. 35.03% of the stock is currently owned by institutional investors.

Insider Transactions at Zevra Therapeutics

In related news, CFO R. Laduane Clifton sold 11,000 shares of the firm's stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total transaction of $86,460.00. Following the sale, the chief financial officer now owns 51,361 shares in the company, valued at approximately $403,697.46. This trade represents a 17.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Neil F. Mcfarlane sold 61,273 shares of the firm's stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $7.86, for a total value of $481,605.78. Following the sale, the chief executive officer now owns 222,060 shares in the company, valued at $1,745,391.60. This trade represents a 21.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 85,773 shares of company stock worth $674,176 over the last 90 days. 2.40% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on ZVRA. Cantor Fitzgerald reissued an "overweight" rating and issued a $25.00 price objective on shares of Zevra Therapeutics in a research note on Wednesday, March 12th. JMP Securities set a $18.00 target price on Zevra Therapeutics in a report on Wednesday, March 12th. Guggenheim increased their target price on Zevra Therapeutics from $20.00 to $22.00 and gave the company a "buy" rating in a research report on Thursday, March 13th. HC Wainwright restated a "buy" rating and set a $20.00 target price on shares of Zevra Therapeutics in a research report on Thursday, March 13th. Finally, Canaccord Genuity Group raised their price target on Zevra Therapeutics from $23.00 to $25.00 and gave the stock a "buy" rating in a research report on Thursday, March 13th. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Zevra Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $22.29.

Zevra Therapeutics Stock Up 0.2 %

NASDAQ:ZVRA traded up $0.02 during trading hours on Monday, reaching $8.02. The company's stock had a trading volume of 78,012 shares, compared to its average volume of 446,449. The stock has a 50 day moving average price of $7.50 and a two-hundred day moving average price of $8.09. Zevra Therapeutics, Inc. has a 12 month low of $4.20 and a 12 month high of $9.76. The company has a debt-to-equity ratio of 0.84, a quick ratio of 2.88 and a current ratio of 2.88. The company has a market capitalization of $438.25 million, a P/E ratio of -4.07 and a beta of 1.87.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last posted its quarterly earnings data on Tuesday, March 11th. The company reported ($0.67) earnings per share for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.28). The business had revenue of $12.00 million during the quarter, compared to analyst estimates of $8.93 million. Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. Equities analysts predict that Zevra Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.